ASHP therapeutic position statement on the identification and treatment of Helicobacter pylori-associated peptic ulcer disease in adults

American Journal of Health-System Pharmacy

Volumn 58, Issue 4, 2001, Pages 331-337

  Buring, Shauna ^a   Russell, Wayne ^b   Meyer, Joette M ^c   Segal, Richard ^d  

^a AUBURN UNIVERSITY   (United States)

^b Pharmacy Department   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

American Society of Health System Pharmacists; Amoxicillin; Antacids; Anti infective agents; Bismuth subsalicylate; Clarithromycin; Clinical pharmacists; Combined therapy; Gastrointestinal drugs; Helicobacter infections; Lansoprazole; Macrolides; Metronidazole; Omeprazole; Penicillins; Proto cols; Ranitidine bismuth citrate; Tetracycline; Tetracyclines; Ulcers

Indexed keywords

AMOXICILLIN; ANTACID AGENT; ANTIINFECTIVE AGENT; BISMUTH SALICYLATE; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MACROLIDE; METRONIDAZOLE; OMEPRAZOLE; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE; TETRACYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM IDENTIFICATION; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; HEALTH CARE ORGANIZATION; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 20644472639     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.4.331     Document Type: Article

References (59)

1. National Institutes of Health Consensus Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272:65-9.
2. Puera DA. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology. 1997; 113:54-8.
3. Soll AH, for the Practice Parameters Committee of the American College of Gastroenterology. Medical treatment of peptic ulcer disease. Practice guidelines. JAMA. 1996; 275:622-9.
4. Robinson DM, Abdel-Rahman SM, Nahata MC. Guidelines for the treatment of Helicobacter pylori in the pediatric population. Ann Pharmacother. 1997; 31:1247-9.
5. Helicobacter pylori and peptic ulcer disease, www.cdc.gov./ulcer/md.htm (accessed. 2000 Oct 2).
6. Wolfe MM, Lichtenstein DR, Singh G. Medical progress: gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340:1888-99.
7. National Digestive Disease Information Clearinghouse. Digestive diseases in the United States: epidemiology and impact. Washington, DC: Public Health Service, 1994; NIH publication no. 94-1447.
8. Sonnenberg A, Everhart J. Health impact of peptic ulcer in the United States. Am J Gastroenterol. 1997; 92:614-20.
9. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995; 333:984-91.
10. Roll J, Weng A, Newman J. Diagnosis and treatment of Helicobacter pylori infection among California Medicare patients. Arch Intern Med. 1997; 157:994-8.
11. Peterson WL, Ciociola AA, Sykes DL and the RBC H. pylori Study Group. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996; 10:251-61.
12. Goodwin CS, Mendall MM, Northfield TC. Helicobacter pylori infection. Lancet. 1997; 349:265-9.
13. Hood HM, Wark C, Burgess PA et al. Screening for Helicobacter pylori and nonsteroidal anti-inflammatory drug use in Medicare patients hospitalized with peptic ulcer disease. Arch Intern Med. 1999; 159:149-54.
14. Centers for Disease Control and Prevention. Knowledge about causes of peptic ulcer disease in the United States: March-April 1997. MMWR. 1997; 46:985-7.
15. Pounder RE, Williams MP. The treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997; 11(suppl 1):35-41.
16. Laine L, Hopkins R, Girardi L. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol. 1998; 93:1409-15.
17. Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med. 1995; 155:922-8.
18. Taylor JL, Zagari M, Murphy K et al. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med. 1997; 157:87-97.
19. Vakil N, Fennerty MB. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol. 1996; 91:239-45.
20. Fendrick AM, McCort JT, Chernew ME et al. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: clinical and economic effects. Am J Gastroenterol. 1997; 92:2017-24.
21. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol. 1998; 93: 2330-8.
22. Breuer T, Goodman KJ, Malaty HM et al. How do clinicians practicing in the U.S. manage Helicobacter pylori-related gastrointestinal diseases? A comparison of primary care and specialist physicians. Am J Gastroenterol. 1998; 98:553-61.
23. Blum AL, Talley NJ, O'Morain C et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998; 339:1875-81.
24. McColl K, Murray L, El-Omar E et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998; 339:1869-74.
25. Friedman LS. Helicobacter pylori and nonulcer dyspepsia. N Engl J Med. 1998; 339:1928-30. Editorial.
26. Fendrick AM, Chernew ME, Hirth RA et al. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med. 1995; 123:260-8.
27. Ofman JJ, Etchason J, Fullerton S et al. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med. 1997; 126:280-91.
28. American Digestive Health Foundation. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology. 1998; 113:S4-8.
29. Atherton JC. Non-endoscopic tests in the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997; 11(suppl 1):11-20.
30. Savarino V, Vigneri S, Celle G. The 13C urea breath test in the diagnosis of Helicobacter pylori infection. Gut. 1999; 45(suppl 1):118-22.
31. Cutler AF, Havstad S, Ma CK et al. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology. 1995; 109:136-41.
32. Savarino V, Bisso G, Pivari M et al. Effect of gastric acid suppression on 13C urea breath test: comparison of ranitidine with omeprazole. Aliment Pharmacol Ther. 2000; 14:291-7.
33. Connor SJ, Seow F, Ngu MC et al. The effect of dosing with omeprazole on the accuracy of the 13C urea breath test in Helicobacter pylori infected subjects. Aliment Pharmacol Ther. 1999; 13:1287-93.
34. Vaira D, Malfertheiner P, Megraud F et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. Lancet. 1999; 354:30-3.
35. Braden B, Teuber G, Dietrich CF et al. Comparison of new faecal antigen test with (13)C-urea breath test for detecting Helicobacter pylori infection and monitoring eradication treatment: prospective clinical evaluation. BMJ. 2000; 320:148.
36. Phull PS, Halliday D, Price AB et al. Absence of dyspeptic symptoms as a test for Helicobacter pylori eradication. BMJ. 1996; 312:349-50.
37. Peura D. Helicobacter pylori: rational management options. Am J Med. 1998; 105:424-30.
38. Prevpac package insert. Deerfield, IL: Tap Pharmaceuticals; 1999 Jan.
39. Biaxin package insert. North Chicago, IL: Abbott Laboratories; 2000 Apr.
40. Borody TJ, Andrews P, Fracchia G et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut. 1995; 37:477-81.
41. Laine L, Estrada R, Trujillo M et al. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996; 10:1029-33.
42. Graham DY, Lew GM, Malaty HM et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992; 102:493-6.
43. Salcedo JA, Al-Kawas F. Treatment of Helicobacter pylori infection. Arch Intern Med. 1998; 158:842-51.
44. Graham D, Lew G, Klein P et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med. 1992; 116:705-8.
45. Goh KL, Navaratnam P, Peh SC et al. Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy. Eur J Gastroenterol Hepatol. 1996; 8:421-3.
46. De Boer WA, Tytgat GN. Treatment of Helicobacter pylori infection. BMJ. 2000; 320:31-4
47. Peterson WL, Fendrick M, Cave DR et al. Helicobacter pylori-related disease. Arch Intern Med. 2000; 160:1285-91.
48. Taylor JL, Zagari M, Murphy K et al. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med. 1997; 157: 87-97.
49. Vakil N, Fennerty B. Cost-effectiveness of treatment regimens for H. pylori infection based on a community practice effectiveness study. Gastroenterology. 1997; 112:A47. Abstract.
50. Meyer JM, Higgins KM, Wang W et al. Evaluation of risk factors in The Surveillance of Helicobacter pylori Antimicrobial Resistance Partnership (SHARP) in the United States from 1993-1999. Gastroenterology. 2000; 118(suppl):A677.
51. Solnick JV. Antibiotic resistance in Helicobacter pylori. Clin Infect Dis. 1998; 27:90-2. Editorial.
52. Graham DY, de Boer WA, Tytgat GNJ. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol. 1996; 91: 1072-6.
53. Berardi RR. Peptic ulcer disease. In: DiPiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 4th ed. Stamford, CT: Appleton & Lange; 1999:548-70.
54. Segarra-Newnham M, Siebert WF. Development and outcomes of an ambulatory clinic for Helicobacter pylori treatment. Hosp Pharm. 1998; 33:205-9.
55. Morreale AP. Pharmacist-managed Helicobacter pylori clinic. Am J Health-Syst Pharm. 1995; 52:183-5.
56. Forster K, Koo J, Heyworth MF. A pharmacist-managed Helicobacter pylori VAMC clinic. P&T. 1999; 24:184-7.
57. Labenz J, Blum AL, Bayerdorffer E et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997; 112:1442-7.
58. Patchin GM, Wieland KA, Carmichael JM. Six months' experience with a pharmacist-run Helicobacter pylori treatment clinic. Am J Health-Syst Pharm. 1996; 53:2081-2.
59. O'Connor HJ. Helicobacter pylori and gastro-oesophageal reflux disease - clinical implications and management. Aliment Pharmacol Ther. 1999; 13:117-27.